-
-
-
-
-
-
-
Ascendis Pharma (ASND) PT Raised to $292 at BofA Securities
-
-
-
-
-
-
-
Ascendis Pharma (ASND) PT Raised to $332 at Stifel
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Ascendis Pharma (ASND) as Yuviwel Approved for Achondroplasia
-
-
-
-
-
-
-
Ascendis Pharma (ASND) Strength Tied to Unconfirmed M&A Chatter
-
-
-
-
-
-
-
TD Cowen on Ascendis Pharma (ASND): 'Physician Survey Shows Smooth Sailing For Yorvipath'
-
-
-
-
-
-
-
Where can biotech stocks go from here? RBC answers
-
-
-
-
-
-
-
Biotech stocks: Q3 earnings preview
-
428,150 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

